Freya Pharma Solutions Breaks New Ground in Female Health Research
Advancing Female Sexual Health: The Launch of Lybrido™ Study
Freya Pharma Solutions, a pharmaceutical company committed to innovative therapies for women facing Female Sexual Disorders (FSD), has recently initiated a Phase II clinical dose-response study. This groundbreaking study evaluates the Lybrido™ concept, focusing on its potential to address Female Sexual Dysfunction (FSD) effectively.
The Impact of Lybrido™ in Treating Sexual Dysfunction
The Lybrido™ study focuses on a dual-action therapy designed to cater to complex female sexual response difficulties. By investigating two specific dose combinations of testosterone and sildenafil, researchers aim to provide a comprehensive evaluation of their effects on arousal. Clitoral blood flow will be measured using a novel technique that quantitatively assesses treatment efficacy, a first of its kind.
Investigator Insights Driving Research
Under the guidance of Principal Investigator Prof. Cobi Reisman and Co-Investigator Dr. Anna Padoa at the Chaim Sheba Medical Center, the study focuses on women diagnosed with acquired generalized Female Sexual Interest/Arousal Disorder (FSIAD). Their approach utilizes Clitoral Doppler Duplex Ultrasound imaging to quantify genital arousal responses, thus emphasizing an objective view towards assessing sexual health in women.
Understanding Female Sexual Disorders
The world of Female Sexual Disorders represents a significant health concern, with many women experiencing low sexual desire and feeling profound impacts on emotional well-being and relationships. According to diagnostic criteria, FSIAD is characterized by persistent reductions in both sexual interest and arousal, which must last for a minimum of six months and cause clinically significant distress.
Challenges and Diagnostic Insights
FSIAD can manifest in various ways, being classified by severity ranging from mild to severe, with further subtypes differentiating between lifelong and acquired conditions. Such classifications highlight the complexities involved in diagnosing and treating female sexual dysfunction, necessitating a customized approach to therapy.
Lybrido™: A New Hope for Women
Freya Pharma's Lybrido™ has undergone various phases of clinical trials, exploring its safety and efficacy in addressing FSIAD. This innovative therapy enhances physiological responses linked to sexual arousal, such as genital swelling and lubrication. With its dual-action formulation, patients may experience increased motivation and responsiveness to sexual stimuli.
Future Directions and Clinical Trials
The ALETTA pivotal study, set to launch in late 2025 across multiple European sites, promises to advance the understanding of Lybrido™'s therapeutic potential. This multi-site clinical study anticipates an enthusiastic response from the scientific community, aiming to provide new insights into the treatment of female sexual disorders.
About Freya Pharma Solutions
Based in Amsterdam, Freya Pharma Solutions focuses on developing solutions for Female Sexual Disorders, relying on over 15 years of solid research. With Lybrido™ at the forefront of its efforts, the company strives to meet a significant unmet medical need, offering women a personalized and convenient on-demand solution.
For further information, please contact:
Freya Pharma Solutions, Amsterdam
Marcel Wijma, Chief Business Officer
Email: marcel@freyapharmasolutions.com
For media inquiries:
LifeSpring Life Sciences Communication, Amsterdam
Leon Melens
Phone: +31 6 538 16 427
Email: lmelens@lifespring.nl
Frequently Asked Questions
What is the purpose of the Lybrido™ study?
The Lybrido™ study aims to evaluate the efficacy of a dual-action therapy for Female Sexual Dysfunction, focusing on physiological measurements of arousal and genital blood flow.
Who is leading the clinical trial?
The clinical trial is led by Prof. Cobi Reisman and Dr. Anna Padoa, who have extensive experience in urology and gynecology, respectively.
What is FSIAD?
FSIAD stands for Female Sexual Interest/Arousal Disorder, a condition characterized by a persistent lack of sexual interest and arousal, often causing distress.
When is the ALETTA study set to begin?
The ALETTA study is expected to commence in late 2025, with enrollment across various European research sites.
How does Lybrido™ differ from traditional treatments?
Lybrido™ utilizes a unique dual-route mechanism that combines testosterone and sildenafil, aiming to enhance both sexual motivation and physiological arousal.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
